[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604943":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":34,"responsibleParty":51,"collaborators":11,"id":53,"slug":11,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":11,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":37,"whyStopped":11,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Canadian Immunization Research Network","NETWORK",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"One HPV vaccine dose received 6 years before recruitment","EXPERIMENTAL",null,[13],"Biological: HPV nonavalent vaccine (Gardasil-9)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"BIOLOGICAL","HPV nonavalent vaccine (Gardasil-9)","One dose HPV nonavalent vaccine",[9],[21],{"name":22,"affiliation":23,"role":24},"Chantal Sauvageau, MD","INSPQ and Laval University","PRINCIPAL_INVESTIGATOR",[26,31],{"name":22,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","418650-5115","6368","chantal.sauvageau@inspq.qc.ca",{"name":32,"role":27,"phone":11,"phoneExt":11,"email":33},"Jo-Ann Costa","jo-anne.costa.ciussscn@ssss.gouv.qc.ca",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Centre de recherche du CHU de Québec-Université Laval","RECRUITING","Québec","Quebec","G1X4S9","Canada",{"type":43,"coordinates":44},"Point",[45,46],-71.21454,46.81228,{"lat":46,"lon":45},[49],{"name":22,"role":27,"phone":50,"phoneExt":11,"email":30},"1+ 418 666-7000",{"type":52,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100604943",false,"NCT07156084","Persistence of Immune Response Six Years After One Dose of 9vHPV Vaccine Among Male and Female Students","CIRN-HPV-ONE","Inclusion Criteria:\n\n* Have received a single dose of 9vHPV vaccine at ages 9-11 during the school year 2019-2020;\n* Not have received any other HPV vaccine doses;\n* Be able to consent to the study.\n\nExclusion Criteria:\n\n* Immunosuppressed (at recruitment or when immunized).",true,"ALL","15 Years","17 Years",{"count":64,"type":65},300,"ESTIMATED","INTERVENTIONAL",[68],"PHASE4","Since the 2019-2020 school year, the province of Quebec (Canada) has been administering one dose of nonavalent (9vHPV) vaccine to students of all genders in Grade 4 of elementary school through the school-based program.\n\nLittle data on the immunogenicity (antibody production) and long-term efficacy of a single dose of the vaccine are available, particularly in boys.\n\nThe primary objective of this study is to assess the persistence of HPV antibodies six years after the administration of a single dose of the 9vHPV vaccine to students aged 9 to 11 years in Grade 4 in 2019-2020.\n\nThe study will be conducted at the CHU de Québec-Université Laval research center.\n\nRecruitment is conducted through school service centers in the Quebec City region. Youth who received only a single dose of the 9vHPV vaccine at the ages of 9-11 in 2019-2020 will be eligible to participate.\n\nApproximately 300 youth will take part in this study: 150 girls and 150 boys.\n\nParticipants will have to answer few questions about their health to ensure their eligibility for the study. For eligible participants consenting to participate a 10 ml (\\\u003C1 tablespoon) blood sample will be taken.",[71],"HPV Vaccine",[73,74,75],"HPV","Vaccination","Schedule","2025-09-24",{"date":78,"type":79},"2025-09-29","ACTUAL",{"date":81,"type":79},"2025-09-23",{"date":83,"type":65},"2026-02",{"name":5,"class":6},1]